| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| P2093 | author name string | B K Park | |
| N R Kitteringham | |||
| G T Tucker | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 477-491 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications | |
| P478 | volume | 41 |
| Q57302808 | 3 The pharmacology of the cytochrome P450 enzyme system |
| Q36053665 | A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs |
| Q43836781 | Alcohol-xenobiotic interactions. Role of cytochrome P450 2E1 |
| Q34378923 | Assessment of drug-drug interactions: concepts and approaches |
| Q34558656 | Clinically significant interactions with drugs used in the treatment of tuberculosis |
| Q35674508 | Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6. |
| Q77512476 | Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets |
| Q41570003 | Drug metabolism: from experiments to regulatory aspects |
| Q51653421 | Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. |
| Q43055978 | Effect of buagafuran on liver microsomal cytochrome P450 in rats |
| Q36912552 | Effect of dehusked Garcinia kola seeds on the overall pharmacokinetics of quinine in healthy Nigerian volunteers |
| Q32174139 | Extrapolation of in vitro enzyme induction data to humans in vivo |
| Q37756278 | Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening |
| Q36388073 | Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias |
| Q37771144 | Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment |
| Q34378928 | Implications and consequences of enzyme induction on preclinical and clinical drug development |
| Q41813941 | In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine |
| Q36263605 | Induction of endogenous pathways by antiepileptics and clinical implications |
| Q71652524 | Lamotrigine and toxic epidermal necrolysis |
| Q34487131 | Liver enzyme induction and inhibition: implications for anaesthesia |
| Q35917069 | Long-cycle treatment with oral contraceptives |
| Q26774479 | Pharmacokinetic drug interactions in liver disease: An update |
| Q33813315 | Pharmacokinetics of haloperidol: an update |
| Q33639741 | Phenobarbital-mediated changes in gene expression in the liver |
| Q44121934 | Pretreatment of rats with the inducing agents phenobarbitone and 3-methylcholanthrene ameliorates the toxicity of chromium (VI) in hepatocytes |
| Q34386829 | Role of drug metabolism in drug discovery and development |
| Q35029490 | Role of variability in explaining ethanol pharmacokinetics: research and forensic applications |
| Q34692592 | Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes |
| Q37368377 | Smoking and anaesthesia: the pharmacological implications |
| Q41725883 | Systemic antifungal agents. Drug interactions of clinical significance |
| Q62546372 | The effect of inducing agents on the metabolism of ethidium bromide by isolated rat hepatocytes |
| Q47722116 | Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism |
| Q34232423 | Toxicogenetics in drug development |
| Q26795769 | Vitamin paradox in obesity: Deficiency or excess? |
Search more.